- Home
- KPTI vs GNLX Comparison
KPTI vs GNLX Comparison
Compare KPTI & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPTI
- GNLX
- Stock Information
- Founded
- KPTI 2008
- GNLX 2001
- Country
- KPTI United States
- GNLX United States
- Employees
- KPTI N/A
- GNLX N/A
- Industry
- KPTI Biotechnology: Pharmaceutical Preparations
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- KPTI Health Care
- GNLX Health Care
- Exchange
- KPTI Nasdaq
- GNLX Nasdaq
- Market Cap
- KPTI 90.7M
- GNLX 85.0M
- IPO Year
- KPTI 2013
- GNLX 2023
- Fundamental
- Price
- KPTI $0.62
- GNLX $3.86
- Analyst Decision
- KPTI Strong Buy
- GNLX Strong Buy
- Analyst Count
- KPTI 4
- GNLX 4
- Target Price
- KPTI $5.00
- GNLX $18.25
- AVG Volume (30 Days)
- KPTI 676.1K
- GNLX 288.1K
- Earning Date
- KPTI 02-27-2025
- GNLX 03-31-2025
- Dividend Yield
- KPTI N/A
- GNLX N/A
- EPS Growth
- KPTI N/A
- GNLX N/A
- EPS
- KPTI N/A
- GNLX N/A
- Revenue
- KPTI $148,442,000.00
- GNLX $8,000.00
- Revenue This Year
- KPTI $5.47
- GNLX N/A
- Revenue Next Year
- KPTI $6.33
- GNLX N/A
- P/E Ratio
- KPTI N/A
- GNLX N/A
- Revenue Growth
- KPTI 1.77
- GNLX N/A
- 52 Week Low
- KPTI $0.58
- GNLX $1.60
- 52 Week High
- KPTI $1.95
- GNLX $9.82
- Technical
- Relative Strength Index (RSI)
- KPTI 40.06
- GNLX 59.89
- Support Level
- KPTI $0.65
- GNLX $3.03
- Resistance Level
- KPTI $0.70
- GNLX $4.23
- Average True Range (ATR)
- KPTI 0.05
- GNLX 0.48
- MACD
- KPTI -0.00
- GNLX 0.09
- Stochastic Oscillator
- KPTI 11.00
- GNLX 51.47
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.